Institutional Owners187 (187 N-Q Owners)

Institutional Stock Ownership and Shareholders

NATIONAL AUSTRALIA BANK LIMITED (ASX:NAB) has 187 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .

NATIONAL AUSTRALIA BANK LIMITED (ASX:NAB) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-11-28 N-Q Advisors Preferred Trust (see advisory)
2017-12-29 N-Q Prudential Investment Portfolios 2 (see advisory)
2018-02-26 N-Q Master Large Cap Series Llc (see advisory)
2017-09-29 N-Q Ishares Inc (see advisory)
2017-09-25 N-Q Legg Mason Bw Global Income Opportunities Fund Inc. (see advisory)
2018-01-26 N-Q VANGUARD WORLD FUND (see advisory)
2017-09-25 N-Q Blackrock Liquidity Funds (see advisory)
2018-02-28 N-Q Goldman Sachs Trust (see advisory)
2017-11-20 N-Q Great-west Funds Inc (see advisory)
2017-09-27 N-Q Advisors' Inner Circle Fund Ii (see advisory)
2017-11-29 N-Q Deutsche Variable Series Ii (see advisory)
2018-01-29 N-Q American Beacon Funds (see advisory)
2017-09-28 N-Q Vanguard Star Funds (see advisory)
2017-10-30 N-Q John Hancock Bond Trust (see advisory)
2018-01-26 N-Q Legg Mason Partners Institutional Trust (see advisory)
2018-02-26 N-Q Blackrock Funds Ii (see advisory)
2018-02-23 N-Q Rbc Funds Trust (see advisory)
2018-01-26 N-Q Templeton Funds (see advisory)
2017-11-27 N-Q John Hancock Hedged Equity & Income Fund (see advisory)
2017-11-22 N-Q Blackrock Index Funds, Inc. (see advisory)
2017-09-26 N-Q Deutsche Global/international Fund, Inc. (see advisory)
2018-03-01 N-Q Investment Managers Series Trust Ii (see advisory)
2017-09-27 N-Q American Independence Funds Trust (see advisory)
2018-01-29 N-Q Wells Fargo Funds Trust (see advisory)
2018-02-28 N-Q Morgan Stanley Institutional Fund Trust (see advisory)
2018-01-23 N-Q Mfs Series Trust Iv (see advisory)
2017-11-28 N-Q North Carolina Capital Management Trust (see advisory)
2017-10-24 N-Q Alps Etf Trust (see advisory)
2017-11-27 N-Q Brighthouse Funds Trust I (see advisory)
2017-09-28 N-Q Advisors' Inner Circle Fund Iii (see advisory)
2017-11-22 N-Q State Street Master Funds (see advisory)
2018-02-27 N-Q Unified Series Trust (see advisory)
2018-01-25 N-Q Ab Portfolios (see advisory)
2017-11-22 N-Q Principal Variable Contracts Funds Inc (see advisory)
2018-02-28 N-Q Seasons Series Trust (see advisory)
2017-09-28 N-Q Powershares Exchange-traded Fund Trust Ii (see advisory)
2017-12-27 N-Q Money Market Obligations Trust (see advisory)
2018-01-24 N-Q PRINCIPAL FUNDS INC (see advisory)
2018-02-28 N-Q EUROPACIFIC GROWTH FUND (see advisory)
2017-11-14 N-Q Russell Investment Funds (see advisory)
2018-02-26 N-Q Blackrock Funds (see advisory)
2017-12-28 N-Q Oppenheimer Ultra-short Duration Fund (see advisory)
2017-11-29 N-Q Natixis Funds Trust I (see advisory)
2018-02-28 N-Q SMALLCAP WORLD FUND INC (see advisory)
2017-11-22 N-Q Quantitative Master Series Llc (see advisory)
2017-11-29 N-Q Aim Growth Series (invesco Growth Series) (see advisory)
2017-11-21 N-Q James Advantage Funds (see advisory)
2017-11-29 N-Q Guggenheim Variable Funds Trust (see advisory)
2018-01-23 N-Q Schwab Strategic Trust (see advisory)
2018-02-20 N-Q Dreyfus Institutional Preferred Money Market Funds (see advisory)
2017-11-28 N-Q Pimco Equity Series (see advisory)
2017-09-26 N-Q Deutsche Market Trust (see advisory)
2018-01-26 N-Q Legg Mason Partners Premium Money Market Trust (see advisory)
2018-01-29 N-Q Goldman Sachs Etf Trust (see advisory)
2017-12-29 N-Q Arrow Etf Trust (see advisory)
2018-01-26 N-Q Vanguard Cmt Funds (see advisory)
2017-11-29 N-Q Vanguard Variable Insurance Funds (see advisory)
2017-11-24 N-Q Transamerica Series Trust (see advisory)
2018-01-29 N-Q Invesco Management Trust (see advisory)
2017-11-22 N-Q COLLEGE RETIREMENT EQUITIES FUND (see advisory)
2017-12-21 N-Q Dreyfus Cash Management (see advisory)
2018-02-28 N-Q Prudential Investment Portfolios, Inc. (see advisory)
2018-02-28 N-Q Professionally Managed Portfolios (see advisory)
2018-03-01 N-Q First Investors Income Funds (see advisory)
2018-02-26 N-Q Master Bond Llc (see advisory)
2017-10-26 N-Q Mfs Series Trust X (see advisory)
2018-01-24 N-Q Deutsche Income Trust (see advisory)
2017-11-29 N-Q Vanguard Bond Index Funds (see advisory)
2017-09-29 N-Q Janus Detroit Street Trust (see advisory)
2018-02-27 N-Q Northern Funds (see advisory)
2018-02-28 N-Q NEW PERSPECTIVE FUND (see advisory)
2018-03-01 N-Q City National Rochdale Funds (see advisory)
2017-11-24 N-Q Sa Funds Investment Trust (see advisory)
2018-01-18 N-Q Etf Series Solutions (see advisory)
2017-09-26 N-Q Morgan Stanley Institutional Liquidity Funds (see advisory)
2017-09-27 N-Q Blackrock Global Allocation Fund, Inc. (see advisory)
2017-09-27 N-Q Payden & Rygel Investment Group (see advisory)
2018-02-27 N-Q Putnam Money Market Fund (see advisory)
2017-11-29 N-Q Bbh Trust (see advisory)
2017-11-29 N-Q Allianz Variable Insurance Products Trust (see advisory)
2017-09-25 N-Q Eagle Series Trust (see advisory)
2017-12-22 N-Q Legg Mason Partners Income Trust (see advisory)
2018-03-01 N-Q Sei Institutional Managed Trust (see advisory)
2018-01-26 N-Q Fidelity Rutland Square Trust Ii (see advisory)
2018-02-26 N-Q Legg Mason Global Asset Management Trust (see advisory)
2018-01-29 N-Q Aim Treasurers Series Trust (invesco Treasurer's Series Trust) (see advisory)
2017-11-29 N-Q Deutsche Securities Trust (see advisory)
2018-03-01 N-Q Intrepid Capital Management Funds Trust (see advisory)
2018-01-26 N-Q Fidelity Commonwealth Trust Ii (see advisory)
2017-12-28 N-Q Franklin Global Trust (see advisory)
2018-02-26 N-Q Blackrock Balanced Capital Fund, Inc. (see advisory)
2017-12-28 N-Q Target Portfolio Trust (see advisory)
2018-01-26 N-Q Vanguard Scottsdale Funds (see advisory)
2018-01-29 N-Q Saratoga Advantage Trust (see advisory)
2017-10-30 N-Q Delaware Group Global & International Funds (see advisory)
2017-09-29 N-Q Global X Funds (see advisory)
2018-01-29 N-Q Northern Lights Fund Trust Iv (see advisory)
2017-10-20 N-Q Strategic Funds, Inc. (see advisory)
2018-01-26 N-Q Templeton Growth Fund Inc (see advisory)
2018-03-01 N-Q Spdr Index Shares Funds (formerly Streettracks Index Shares Funds) (see advisory)
2018-02-27 N-Q Lattice Strategies Trust (see advisory)
2017-11-29 N-Q Ubs Funds (see advisory)
2017-11-29 N-Q Allianz Variable Insurance Products Fund Of Funds Trust (see advisory)
2018-02-27 N-Q Putnam Asset Allocation Funds (see advisory)
2017-09-20 N-Q Dreyfus Index Funds Inc (see advisory)
2018-02-28 N-Q Wisdomtree Trust (see advisory)
2017-11-28 N-Q Charles Schwab Family Of Funds (see advisory)
2017-11-27 N-Q Voya Variable Portfolios Inc (see advisory)
2018-03-01 N-Q First Trust Exchange-traded Fund Ii (see advisory)
2017-12-29 N-Q Adviser Managed Trust (see advisory)
2017-12-29 N-Q Income Fund Of America (see advisory)
2018-02-26 N-Q Blackrock Bond Fund, Inc. (see advisory)
2018-02-27 N-Q Bernstein Sanford C Fund Inc (see advisory)
2018-01-26 N-Q Fidelity Salem Street Trust (see advisory)
2018-01-26 N-Q Master Portfolio Trust (see advisory)
2018-01-29 N-Q First American Funds Inc (see advisory)
2018-02-26 N-Q Ab Global Bond Fund, Inc. (see advisory)
2018-02-26 N-Q TIAA-CREF FUNDS (see advisory)
2017-11-28 N-Q Anchor Series Trust (see advisory)
2017-11-28 N-Q Pimco Etf Trust (see advisory)
2018-03-01 N-Q Optimum Fund Trust (see advisory)
2017-11-27 N-Q Voya Balanced Portfolio Inc (see advisory)
2017-10-27 N-Q Ab Global Risk Allocation Fund, Inc. (see advisory)
2018-01-24 N-Q Capitol Series Trust (see advisory)
2017-09-27 N-Q Advisors' Inner Circle Fund (see advisory)
2018-02-27 N-Q Doubleline Funds Trust (see advisory)
2017-09-29 N-Q Tax-managed International Equity Portfolio (see advisory)
2018-03-01 N-Q Value Line Asset Allocation Fund Inc (see advisory)
2017-11-29 N-Q Deutsche Institutional Funds (see advisory)
2017-11-29 N-Q New Covenant Funds (see advisory)
2017-10-24 N-Q Federated Global Allocation Fund (see advisory)
2017-11-29 N-Q Gabelli Dividend & Income Trust (see advisory)
2018-02-28 N-Q Ishares Trust (see advisory)
2017-09-28 N-Q Mfs Series Trust Xv (see advisory)
2017-11-28 N-Q Pax World Funds Series Trust I (see advisory)
2017-09-29 N-Q Ishares U.s. Etf Trust (see advisory)
2018-01-25 N-Q Dbx Etf Trust (see advisory)
2017-11-29 N-Q Crm Mutual Fund Trust (see advisory)
2017-12-28 N-Q Eaton Vance Growth Trust (see advisory)
2017-11-28 N-Q Ab Cap Fund, Inc. (see advisory)
2017-09-25 N-Q Thrivent Core Funds (see advisory)
2017-09-28 N-Q Mfs Series Trust Ix (see advisory)
2017-11-29 N-Q Lord Abbett Global Fund Inc (see advisory)
2017-09-28 N-Q Vanguard International Equity Index Funds (see advisory)
2017-11-28 N-Q American Balanced Fund (see advisory)
2017-09-28 N-Q Jpmorgan Trust Ii (see advisory)
2018-03-01 N-Q Aqr Funds (see advisory)
2018-01-26 N-Q Short-term Bond Fund Of America (see advisory)
2018-03-01 N-Q Loomis Sayles Funds I (see advisory)
2017-09-28 N-Q Jpmorgan Trust I (see advisory)
2017-11-28 N-Q Guidestone Funds (see advisory)
2018-02-28 N-Q Franklin Templeton Etf Trust (see advisory)
2017-09-22 N-Q J.p. Morgan Exchange-traded Fund Trust (see advisory)
2018-01-26 N-Q Vanguard Money Market Reserves (see advisory)
2018-02-28 N-Q Vanguard Malvern Funds (see advisory)
2017-11-28 N-Q Jnl Investors Series Trust (see advisory)
2017-11-28 N-Q Morgan Stanley Asia-pacific Fund, Inc. (see advisory)
2017-11-29 N-Q Prudential Series Fund (see advisory)
2018-02-28 N-Q Vanguard Wellesley Income Fund (see advisory)
2017-11-21 N-Q Neuberger Berman Advisers Management Trust (see advisory)
2017-09-25 N-Q Western Asset Global Corporate Defined Opportunity Fund Inc. (see advisory)
2018-03-01 N-Q Pimco Funds (see advisory)
2017-10-25 N-Q Western Asset Funds Inc (see advisory)
2018-02-26 N-Q Allianzgi Institutional Multi-series Trust (see advisory)
2018-02-28 N-Q Guggenheim Funds Trust (see advisory)
2017-12-28 N-Q Putnam Funds Trust (see advisory)
2018-02-28 N-Q Gps Funds I (see advisory)
2017-09-26 N-Q Legg Mason Etf Investment Trust (see advisory)
2018-02-28 N-Q Steben Alternative Investment Funds (see advisory)
2017-11-22 N-Q State Street Navigator Securities Lending Trust (see advisory)
2018-02-28 N-Q Ivy Funds (see advisory)
2017-10-30 N-Q Claymore Exchange-traded Fund Trust 2 (see advisory)
2018-02-27 N-Q John Hancock Funds Iii (see advisory)
2018-01-29 N-Q Short Term Investments Trust (see advisory)
2017-09-20 N-Q Dreyfus/laurel Funds Inc (see advisory)
2018-02-27 N-Q Massmutual Select Funds (see advisory)
2017-09-20 N-Q Citizensselect Funds (see advisory)
2017-11-28 N-Q Pax World Funds Series Trust Iii (see advisory)
2018-01-22 N-Q Blackrock Floating Rate Income Strategies Fund, Inc. (see advisory)
2017-11-28 N-Q Bond Fund Of America (see advisory)
2017-11-22 N-Q State Street Institutional Investment Trust (see advisory)
2017-11-24 N-Q Mfs Variable Insurance Trust Iii (see advisory)
2017-09-29 N-Q American Beacon Institutional Funds Trust (see advisory)
2018-03-01 N-Q Sei Institutional International Trust (see advisory)
2017-09-29 N-Q Master Trust (see advisory)
2018-03-01 N-Q Calvert Responsible Index Series, Inc. (see advisory)
2017-09-28 N-Q Vanguard Charlotte Funds (see advisory)

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.


  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( ASX:NAB / NATIONAL AUSTRALIA BANK LIMITED ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...